Shukra Pharmaceuticals has filed the notice for its 33rd Annual General Meeting (AGM) with stock exchanges. The meeting is scheduled for Monday, September 28, 2026, at 12:00 pm via Video Conferencing.

The company previously rescheduled the AGM from September 22, 2026, citing administrative exigencies. The notice confirms the revised date and outlines the ordinary business to be transacted.

Agenda Items

The AGM agenda includes four key items:

1. Adoption of Financials: Consideration and adoption of the audited financial statements for the financial year ended March 31, 2026, along with the reports of the Board of Directors and Auditors.
2. Dividend Declaration: Approval and declaration of a final dividend of ₹0.01 per equity share of face value ₹1 each for FY26. This represents a 1% dividend payout.
3. Director Re-appointment: Re-appointment of Ms. Sanskruti Patel (DIN: 07108631) as an Executive Director. She retires by rotation and offers herself for re-appointment.
4. Additional Independent Director: Regularisation of the appointment of Mr. Dinesh Chauhan (DIN: 11456530) as an Additional Independent Director. This requires a Special Resolution.

Schedule and Logistics

The Register of Members and Share Transfer Books will remain closed from Tuesday, September 22, 2026, to Monday, September 28, 2026 (both days inclusive). This closure facilitates the preparation of the list of members entitled to attend and vote at the AGM.

The remote e-voting period and cut-off date will be aligned with the revised AGM schedule. Specific details regarding e-voting will be provided in the final notice circulated to shareholders.

All other appointments approved in the board meeting dated August 22, 2026, remain unchanged. This includes the appointment of Mrs. Rupal Patel, Practicing Company Secretary, as Scrutinizer.

Shukra Pharmaceuticals Limited has issued a postal ballot notice to shareholders seeking approval for its proposed name change to "Shukra Medtech Limited" and related alterations to its Memorandum of Association (MOA). The remote e-voting period commences on August 28, 2026, and concludes on September 26, 2026.

The board of directors approved the strategic shift during a meeting held on August 22, 2026. The proposals require shareholder consent via postal ballot and regulatory clearances from the Registrar of Companies. The company also convened its 33rd Annual General Meeting (AGM) for September 25, 2026.

Voting Timeline and Process

The company engaged National Securities Depository Limited (NSDL) to facilitate the e-voting process. Shareholders whose names appear on the register as of the cut-off date, August 21, 2026, are eligible to vote. The voting rights are proportional to the paid-up equity share capital held on this date.

Mrs. Rupal Patel, Practicing Company Secretary, has been appointed as the Scrutinizer to ensure the fairness and transparency of the e-voting process. The results will be declared within two working days or three days, whichever is earlier, from the conclusion of the voting period.

Strategic Expansion into MedTech

The board sanctioned the alteration of the Main Objects Clause in the MOA to enable operations in Medical Technology (MedTech). This expansion allows the company to undertake activities including:

• Research, development, design, and manufacturing of medical devices, equipment, and diagnostic systems
• Development of surgical robotic systems, implantable devices, and wearable healthcare devices
• Creation of artificial intelligence-based healthcare technologies and digital health platforms
• Distribution, marketing, and trading of medical technology products and solutions

The company stated this shift aims to provide a broader corporate identity and explore business opportunities in the medical technology sector alongside existing pharmaceutical activities. The explanatory statement notes that the company has received encouraging business interest and developed strategic connections in the MedTech sector.

Regulatory Compliance and Auditor Certificate

The proposed name change requires compliance with Regulation 45 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. An independent certificate from Shah Sanghvi & Associates confirms the company’s adherence to specific conditions:

• Time elapsed: More than one year has passed since the last name change.
• Asset investment: The amount invested in the new activity exceeds 50% of the company’s total assets.
• Revenue contribution: No revenue has been generated from the new activity in the preceding year, meaning the condition requiring 50% of total revenue from the new activity is not satisfied. However, the change is permitted under other clauses of the regulation.

AGM Details and Corporate Governance

The board fixed the date for the 33rd Annual General Meeting (AGM) for September 25, 2026, at 12:00 pm via Video Conferencing (VC). Key governance matters addressed include:

• Approval of the Director's Report and Secretarial Audit Report for the year ended March 31, 2026
• Appointment of Mrs. Rupal Patel as Scrutinizer for Remote E-voting and voting at the AGM
• Closure of the Register of Members and Share Transfer Books from September 19, 2026, to September 25, 2026 (both days inclusive)

Trading Window Closure

In compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for designated employees remained closed from August 17, 2026, to August 24, 2026. This closure continues until 48 hours after the public announcement of the board meeting outcome.